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Abstract: Ovarian cancer, one of the most common gynecological malignancies, has an 
aggressive  phenotype.  It  is  necessary  to  develop  novel  and  more  effective  treatment 
strategies against advanced disease. Protein tyrosine kinases (PTKs) play an important role 
in  the  signal  transduction  pathways  involved  in  tumorigenesis,  and  represent  potential 
targets for anticancer therapies. In this study, we performed cDNA subtraction following 
polymerase  chain  reaction  (PCR)  using  degenerate  oligonucleotide  primers  to  identify 
specifically overexpressed PTKs in ovarian cancer. Three PTKs, janus kinase 1, insulin-like 
growth factor 1 receptor, and discoidin domain receptor 1 (DDR1), were identified and 
only DDR1 was overexpressed in all ovarian cancer tissues examined for the validation by 
quantitative real-time PCR. The DDR1 protein was expressed in 63% (42/67) of serous 
ovarian cancer tissue, whereas it was undetectable in normal ovarian surface epithelium. 
DDR1  was  expressed  significantly  more  frequently  in  high-grade  (79%)  and  advanced 
stage  (77%)  tumors  compared  to  low-grade  (50%)  and  early  stage  (43%)  tumors.  The 
expression of the DDR1 protein significantly correlated with poor disease-free survival. 
Although its functional role and clinical utility remain to be examined in future studies, our 
results suggest that the expression of DDR1 may serve as both a potential biomarker and a 
molecular target for advanced ovarian cancer. 
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1. Introduction  
Ovarian  cancer,  one  of  the  most  common  gynecological  malignancies,  is  an  aggressive  cancer 
associated  with  high  morbidity  and  mortality,  especially  in  the  case  of  advanced  disease. 
Unfortunately, ovarian cancer is rarely diagnosed in its early, most curable stages, and the tumors are 
already  disseminated  abdominally  in  75%  of  patients  at  the  time  of  diagnosis.  The  tumor  grade, 
histological  type,  and  presence  of  residual  disease  after  initial  surgery  are  also  important 
clinicopathological factors related to patient outcome [1]. To improve the prognosis of ovarian cancer, 
it is vital to clarify the molecular mechanisms involved in the progression of this disease, and to 
develop novel and more effective treatment strategies against advanced disease. 
Protein tyrosine kinases (PTKs) play an important role in the signal transduction pathways that 
control cell proliferation and differentiation, and are involved in tumorigenesis. Many PTKs have been 
shown to act as oncogenes, and analysis of PTK expression in malignant cells will lead to a better 
understanding of oncogenesis, which in turn may lead to novel therapies based on selective inhibition 
of  the  PTKs  involved  in  malignant  transformation  [2].  Various  targeted  therapeutics  have  been 
explored for the management of ovarian cancer. PTKs such as Her2/neu, the epidermal growth factor 
receptor  (EGFR),  and  vascular  endothelial  growth  factor  (VEGF),  represent  potential  targets  for 
ovarian cancer, and agents targeting these molecules are already being used in the clinic for other 
diseases [3–5]. The PTKs may also provide an important predictive marker for therapeutic response 
and  patient  outcome  [6,7].  It  is  important  to  identify  predictive  PTKs  to  identify  targeted 
subpopulations of patients who will respond to both the existing tyrosine kinase inhibitors (TKIs) and 
to new agents developed against new targets, and to obtain a better understanding of the underlying 
mechanisms of resistance to the existing agents so that new compounds can be developed to overcome 
this resistance. 
The expression of PTKs can easily be determined by RT-PCR using degenerate primers which 
recognize common, relatively invariable cDNA sequences of members of the PTK family. PCR-based 
cDNA subtraction offers an efficient method for selectively amplifying differentially expressed genes. 
This method is particularly well-suited for the identification of target cDNAs that correspond to rare 
transcripts, which are typically the most difficult to obtain. 
In this study, we have combined cDNA subtraction and polymerase chain reaction (PCR) using 
degenerate oligonucleotide primers representing conserved amino acid sequences within the tyrosine 
kinase domain to identify specifically overexpressed PTKs in serous ovarian cancer. The PTKs that 
were identified were subsequently examined for their potential association with the clinicopathological 
factors and patient outcome. 
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2. Materials and Methods 
2.1. cDNA Subtraction and Degenerate PCR 
Primary serous papillary ovarian cancer tissue samples  and their corresponding normal  ovarian 
tissue samples were obtained from three patients who underwent primary debulking surgery at the 
Niigata University Medical and Dental Hospital. Total RNA was extracted using an RNeasy Miniprep 
Kit (Qiagen), and poly(A)RNA was isolated using the FastTrack 2.0 Kit (Invitrogen) according to the 
manufacturer’s instructions. The cDNA was synthesized, and cDNA subtraction was performed for 
each patient using a PCR-select cDNA subtraction kit (Clontech) according to the manufacturer’s 
instructions. To select truly overexpressed PTKs in the cancer tissue, cDNA subtraction was performed 
between the tumor cDNA as a tester and 5-times the amount of normal ovarian cDNA as a driver. The 
subtracted cDNA fragments were amplified by suppression PCR in order to enrich the differentially 
expressed sequence and to reduce background. The final products of cDNA subtraction were further 
amplified with primers corresponding to consensus sequences for PTKs. Primers were synthesized 
corresponding to the amino acids HRDLAARN and DVWS(F/Y)G(I/V), which are highly conserved 
sequences in the catalytic domains of PTKs. The products of the degenerate PCR were subcloned and 
then sequenced. 
2.2. Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction Assay 
Quantitative RT-PCR was performed to validate the expression of each clone identified by cDNA 
subtraction and degenerate PCR using Taqman probes. Tumor samples from 8 patients with serous 
ovarian cancer and their corresponding normal ovarian tissue were used for the analysis. Total RNA 
was isolated and processed with the RNeasy Miniprep Kit (Qiagen). A TaqMan two-step kit (Applied 
Biosystems)  was  utilized  for  all  RT  reactions.  The  High  Capacity  cDNA  Archive  kit  utilizes  a 
proprietary mixture of 10 ×  random primers, MultiScribe ™ Reverse Transcriptase (50 U/µL) and  
10 ×  Reverse Transcription Buffer and 25 ×  dNTPs for the RT reaction. RT reactions were incubated 
at 25 ° C for 10 min, followed by 37 ° C for 120 min in a thermal cycler. After cDNA synthesis was 
performed during the second step, RT-PCR was then performed in an ABI PRISM 7900 in a 50 μL 
final volume with 1 μL of the cDNA template, 10 μM of primers and 5 μM of TaqMan Probe, and 
enzymes from the 2 ×  TaqMan Universal PCR Master Mix (ABI) according to the manufacturer’s 
protocol. The thermal cycling conditions were: 2 min at 50 ° C, 10 min at 95 ° C, followed by 40 cycles 
of 15 s at 95 ° C and 1 min at 60 ° C. The primer sequences were designed by Operon Biotechnology 
(Tokyo, Japan), and were as follows; IGF1-R: forward primer: 5’-ACTTCTGCGCCAACATCCTCA-3′; 
reverse  primer:  5’-CCCTTTAGTCCCCGTCACTTCC-3’,  JAK1:  forward  primer:  
5’-AGAGGCATATAAAATTTAGATTGC-3’;  reverse  primer:  5′-TGTCCTTGTTGAGAGTGAACA-
3’,  DDR1:  forward  primer:  5’-ATGGAGCAACCACAGCTTCTC-3’;  reverse  primer:  
5’-CTCAGCCGGTCAAACTCAAACT-3’,  and  GAPDH:  forward  primer:  
5’-GGCTCCCACCTTTCTCATCC-3’;  reverse  primer:  5’-GATGTGGGGAGTACGCTGC-3’.  The 
TaqMan-probes were obtained from Applied Biosystems. 
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2.3. Immunohistochemistry 
Archival tissue from patients with ovarian cancer removed at debulking surgery and normal ovaries 
removed during surgery for benign conditions were used for immunohistochemical analysis. H&E-stained 
sections of each sample were reviewed by a pathologist, and areas corresponding to tumor tissue were 
marked. Immunohistochemistry (IHC) was performed on 67 serous ovarian cancer tissue specimens 
and  5  normal  ovarian  tissue  specimens  that  were  paraffin-embedded  and  cut  into  4-µm -thick  
sections and mounted on positive charge-coated slides. Tissue sections were dried overnight in a 45 ° C  
oven.  For  antigen  visualization,  the  EnVision/HRP  system  and  DAB+  (Dako)  were  used.  The 
immunohistochemical procedure was optimized by testing different antigen retrieval methods using 
negative and positive controls. An anti-DDR1 antibody (Santacruz) was added at a 1:100 dilution to 
each section and incubated for 60 min at room temperature. The IHC results were scored based on the 
staining intensity as negative and positive. Immunoreactivity was scored as follows: the numbers of 
DDR1 positive cells were counted out of 100 cells in three different high power fields and judged as 
“positive” when >50% of cells were positively stained according to previous reports [8]. Cases were 
classified into two groups: group 1 (negative) included the cases with negative staining and less than 
50% of staining, group 2 (positive) included cases with more than 50% of staining. 
2.4. Association between the Expression of DDR1 Protein in Ovarian Cancer and the Clinical Disease 
Stage, Tumor Grade, and Patient Outcome 
The clinical data for this immunohistochemical staining study were collected from 67 consecutive 
unselected patients with primary epithelial ovarian cancer who had undergone surgery at the Niigata 
University Dental and Medical Hospital between 2000 and 2004. Only patients with a histological 
diagnosis of serous papillary ovarian cancer were included in this study, and those with borderline 
tumors  were  excluded.  All  tumors  were  graded  and  staged  according  to  the  FIGO  (International 
Federation of Gynecology and Obstetrics) classification. All patients provided consent according to the 
institutional review board of Niigata University Dental and Medical Hospital, Niigata, Japan. 
3. Results 
After screening ovarian cancer tissue samples by the PCR-based cDNA subtraction and degenerate 
PCR for selection of the clones of differentially overexpressed PTKs, we randomly selected 202 clones. By 
sequencing analyses, 140 clones were revealed to be identical to janus kinase 1 (JAK1), 30 to the 
insulin-like growth factor 1 receptor (IGF1-R), and eight to the discoidin domain receptor 1 (DDR1). 
The other 24 clones were unidentified genes.  
We performed quantitative real-time PCR to validate whether the three PTKs were constitutively  
overexpressed  in  ovarian  cancer  using  eight  serous  ovarian  cancer  tissue  and  their  corresponding 
normal ovarian tissue samples. The DDR1 gene was overexpressed in all eight individuals, whereas the 
expression levels of JAK1 and IGF1-R were not increased in half of the ovarian cancer tissue samples 
(Figure 1). The DDR1 expression level in the ovarian cancer tissue samples was increased 6.7 fold on 
average compared with normal ovarian tissue. Int. J. Mol. Sci. 2011, 12                      
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Figure  1.  Quantitative  real-time  PCR  for  the  validation  of  overexpression  of  three 
identified genes in ovarian cancer. Quantitative real-time PCR was performed to validate 
the overexpression of three identified PTKs, JAK1, IGF1R, and DDR1, in ovarian cancer. 
Fold  change  in  the  expression  between  ovarian  cancer  tissue  and  their  corresponding 
normal  ovarian  tissue  samples  are  shown  with  black  bars.  The  DDR1  gene  was 
overexpressed in all eight individuals, whereas the expression levels of JAK1 and IGF1-R 
were not increased in half of the ovarian cancer tissue samples. 
 
To characterize the expression of DDR1, we carried out immunohistochemical analysis of 67 primary 
serous ovarian cancers from patients who had not received any prior treatment, obtained from primary 
debulking surgery. As demonstrated in Figure 2, no DDR1 staining was present in epithelial cells in 
normal ovary and serous adenoma, but the expression was increased in the ovarian cancer cells.  
The DDR1 protein was highly expressed in 69% (46/67) of serous ovarian cancer tissue samples. 
Moreover, DDR1 protein expression was correlated with the pathologic grade of the tumor and the 
clinical disease stage at the time of surgery. As shown in Table 1, DDR1 was expressed significantly 
more frequently in FIGO Grade 1 (50%) compared to combined G2 and G3 (79%) tumors (p = 0.015).  
We next compared the clinical disease stage for patients with different levels of DDR1 expression. 
Given the limited number of samples, the stage I and II samples were combined (early stage), as were the 
stage III and IV samples (advanced stage). The expression of DDR1 in early stage samples was 50%, 
while it was 82% in advanced stage tumors. There were significant differences in DDR1 expression found 
between advanced stage tumors compared with tumors found in the early stage (p = 0.006) (Table 2). 
DDR1  expression  was  then  examined  for  an  association  with  disease-free  survival  and  overall 
survival using Kaplan-Meier survival analysis with the log-rank statistic to determine significance. 
Kaplan-Meier survival curves generated for tumor DDR1, high versus low expression, are given in 
Figure 3. High tumor DDR1 expression was significantly associated with a poor outcome for disease-free 
survival (p = 0.032). With regard to overall survival, high tumor DDR1 expression showed a tendency 
toward a poorer outcome, but this trend was not statistically significant (p = 0.064). 
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Figure  2.  Representative  immunohistochemistry  staining  of  DDR1.  Immunohistochemical 
analysis  with  the  DDR1  antibody  revealed  negative  DDR1  protein  expression  in  
(A) normal ovary and (B) serous cystadenoma, whereas positive expression was observed 
in (C) serous ovarian cancer cells. (A) no DDR1 staining in surface epithelium of normal 
ovary (black arrow); (B) no DDR1 staining in epithelial lining cells in serous cystadenoma 
(black arrow); (C) representative staining pattern of serous ovarian cancer tissue shows 
positive DDR1 staining in most serous adenocarcinoma cells (black arrow) with negative 
DDR1  staining  in  stromal  cells  (white  arrow);  (D)  in  placenta  (positive  control);  all 
trophoblastic  cells  show  positive  DDR1  staining.  Original  magnification:  × 40,  scale  bar:  
50 µ m (white bar). 
 
Table 1. DDR1 expression in patients with ovarian cancer according to tumor grading. 
  DDR1 positive  DDR1 negative 
G1  12 
       
P = 0.015 
12     
     
G2  21  5     
G3  13  4     
         
 
   Int. J. Mol. Sci. 2011, 12                      
 
 
977 
Table 2. DDR1 expression in patients with ovarian cancer according to clinical staging. 
Stage   Cases No.  DDR1 positive  Percent of DDR1 positive 
         
50.0 
   
p = 0.006 
I  22  11       
II  6  3       
     
           
III  35  29   
82.1 
   
IV  4  3     
total  67  46  68.7   
Figure  3.  Patient  outcome  according  to  the  DDR1  expression  in  patients  with  serous 
ovarian cancer. Kaplan-Meier analysis of (A) disease-free survival and (B) overall survival, 
according to DDR1 expression levels. Significant trend for shorter disease-free survival 
was observed in the DDR1 positive group (p = 0.043). 
 
4. Discussion 
In  the  present  study,  we  identified  DDR1  as  a  differentially  expressed  PTK  gene  in  primary 
epithelial serous ovarian cancer using a combination of cDNA subtraction and degenerate PCR-based 
cloning. DDR1 was more highly expressed in ovarian cancer samples compared with normal ovarian 
tissues. We were able to show that DDR1 expression is associated with the tumor grade and clinical 
disease stage, and is inversely correlated with the survival outcome of patients. 
Receptor tyrosine kinases control a wide array of cellular responses, including the regulation of cell 
growth, differentiation, migration, metabolism, and survival. DDR1 was independently isolated as a novel 
receptor tyrosine kinase by several laboratories from human, mouse, and rat tissue in the 1990s [9–11]. 
DDR1 is characterized by a structural domain of 160 amino acids in its extracellular part that exhibits 
strong sequence similarity to the Dictyostelium discoideum protein discoidin 1, coagulation factors V 
and VIII, and to a Xenopus laevis recognition protein, A5. DDR1 is activated by collagen type I, II, III, 
V,  and  XI.  Activation  of  DDR1  by  collagen  results  in  its  sustained  intracellular  phosphorylation. 
DDR1 is widely expressed in epithelial cells of both fetal and adult organs. Although the physiological Int. J. Mol. Sci. 2011, 12                      
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functions  of  DDR1  are  not  fully  understood,  DDR1  signaling  is  essential  for  cerebellar  granule 
differentiation [12], arterial wound repair [13], and mammary gland development [14]. It is clear that 
DDR1 is involved in cell interactions with the extracellular matrix, and that it controls adhesion and 
cell motility [15,16]. 
DDR1 was found to be overexpressed in breast, brain, colon, and lung cancers, thus suggesting that 
this receptor may play a role in the tumorigenesis of epithelial cancers [17–20]. In breast cancer, 
DDR1  was  overexpressed  in  both  primary  breast  tumor  samples  and  metastasis-containing  lymph 
nodes [21]. DDR1 protein levels were elevated in 100% of patients with primary and metastatic brain 
tumors [18], in 61% of patients with non-small cell lung cancer, and in 64% of patients with invasive 
lung  adenocarcinoma  [22].  Thus,  DDR1  expression  appears  to  be  elevated  in  a  variety  of  human  
cancers.  Consistent  with  studies  of  DDR1  in  these  solid  tumors,  elevated  levels  of  DDR1  were  
seen  in  serous  ovarian  cancer  in  this  study.  Our  results  were  also  consistent  with  a  study  by 
Heinzelmann-Schwarz et al. that reported that DDR1 proteins are highly overexpressed in all histological 
subtypes of epithelial ovarian cancer compared with the normal ovarian surface epithelium [23]. 
The overexpression of DDR1 in these different human cancers suggests that it may have a function 
in tumor progression. It has been reported that DDR1 is overexpressed in high-grade brain, esophageal, 
and breast cancers, and high expression of DDR1 was associated with a significantly poorer survival in 
several cohorts of patients with brain, breast, and lung cancers [18,22,24–26]. In the present study, we 
showed that DDR1 expression was associated with high-grade and advanced stage tumors, as well as 
with poor survival in patients with ovarian cancer. These results were not consistent with those from 
previous study by Heinzelmann-Schwarz et al. [23]. They reported that expression of membranous 
DDR1 did not correlate with survival of patients. Recently Mihai C. et al. proposed the model of the 
DDR1 activation mechanism by analyzing the cellular distribution of DDR1 [27]. They showed the 
aggregation and cellular internalization of the receptor following collagen stimulation. In this study, 
we evaluated both membranous and cytoplasmic DDR1 expression and did not analyze the intensity of 
the staining. Although the activation process of DDR1 still remains largely unknown, evaluation of the 
cellular  distribution  or  intensity  of  DDR1  expression  might  be  required  to  analyze  the  precise 
biological  activity  of  DDR1.  Several  recent  studies  have  examined  the  molecular  mechanisms 
underlying the role of DDR1 in tumor progression, invasion, and metastasis. One study showed that 
DDR1  expression  may  be  regulated  during  the  cell  cycle,  because  overexpression  of  p53  in 
osteosarcoma cells induces DDR1 expression [28]. Ongusaha et al. have reported that DDR1 is a direct 
p53 transcriptional target, and that inhibition of DDR1 function resulted in increased apoptosis through 
a caspase-dependent pathway [29]. Other published data imply that the Wnt-5a pathway may overlap 
with  DDR1  signaling  [26].  Shintani  et  al.  have  shown  that  DDR1  promotes  the  epithelial  to 
mesenchymal transition in response to collagen I stimulation in human pancreatic cancer cells [30]. 
Although experimental evidence argues against a classiﬁcation of DDR1 as a transforming oncogene, 
subsequent steps after the initial cellular transformation, such as invasion and metastasis, might be 
mediated by DDR1. 
One of the major characteristics of an ideal biomarker or target for molecular therapeutics is that it 
is absent in benign tissue and present in the targeted malignancies. Our results showed no protein 
expression of DDR1 in normal ovarian epithelial cells. It has been reported that DDR1 expression is 
highest in the brain, lungs, placenta and kidneys, and is present at low levels in various other adult Int. J. Mol. Sci. 2011, 12                      
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tissues, such as melanocytes, the heart, liver, skeletal muscle, pancreas, and ovaries [31]. Elevated 
levels of DDR1 protein expression appear to be highly predictive of the presence of ovarian cancer. 
Although it would be nonspecific for ovarian cancer (because it could  also indicate various other 
malignancies), the levels of DDR1 expression in body fluid or serum may have clinical prognostic 
utility as a biomarker for cancer. 
Various  targeted  therapeutics  have  been  explored  for  the  management  of  ovarian  cancer.  In 
addition, numerous studies have examined the use of TKIs, including monoclonal antibodies against 
Her2/neu [4], other EGFRs [3], and VEGF [5], and small molecule tyrosine kinase inhibitors targeting 
various  other  receptors,  including  the  EGFR  and  VEGFR  [32,33].  A  recent  study  showed  that 
dasatinib, a multi-targeted TKI, inhibits DDR1, in addition to inhibiting BCR-ABL [34]. Moreover, 
DDR1 has also been identified as a potential target of other BCR-ABL inhibitors, including imatinib [35]. 
These inhibitors of DDR1 may prove to be therapeutically beneficial for the treatment of advanced 
ovarian cancer. 
5. Conclusion 
In summary, we have identified DDR1 as a differentially overexpressed PTK in ovarian cancer 
tissue using a combination of cDNA subtraction and degenerate PCR-based cloning. The association 
between DDR1 expression, tumor grade, clinical disease stage, and patient outcome suggests an in vivo 
role for this signal transduction pathway in ovarian cancer. The mechanisms by which DDR1 affects 
signaling cascades involved in tumor progression, invasion, and metastasis have not yet been fully 
characterized. Further investigation of DDR1 as a clinical biomarker and as a therapeutic target is 
warranted, especially for ovarian cancer. 
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